Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions
by Julia Kollewe from on (#6A2DR)
Swiss firm's withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment
The Swiss pharmaceutical firm Novartis has ditched plans for a large clinical trial in the UK, in a further blow to the government's efforts to make Britain an attractive place for research and investment after Brexit.
The company decided to scrap the Orion-17 trial of its cholesterol-lowering drug Leqvio, involving 40,000 patients in partnership with NHS England.
Continue reading...